BIOMAT Database Logo BIOMAT Database Logo

[Effect of corticosteroids, quinacrine and L-652, 731 on experimental aggregation of polymorphonuclear leukocytes induced by complement and platelet activating factor (PAF)]. 1988

A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Cátedra de Patología y Clínica Médicas I, Hospital Clínico Universitario Virgen Macarena, Sevilla, España.

The effects of 6-methylprednisolone sodium succinate, quinacrine and the synthetic anti-PAF compound L-652,731 were studied on the PAF and complement induced aggregation of rabbit polymorphonuclear leukocytes in vivo. High doses (100-250 mg/kg) of corticosteroid were able to abrogate PAF and complement induced aggregation. Quinacrine (1.25 mg/kg), and L-652,731, partially precluded complement-depending aggregation. The L-652,731 dose employed was just enough to prevent PAF induced aggregation. These results suggest that in those pathological conditions in which polymorphonuclear aggregation occurs, factors other than those derived from plasmatic complement system activation, and laboring jointly with it, may be involved.

UI MeSH Term Description Entries
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D008776 Methylprednisolone Hemisuccinate A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies. Methylprednisolone Succinate,6 alpha-Methylprednisolone Sodium Hemisuccinate,A-MethaPred,Methylprednisolone Hemisuccinate Monosodium Salt,Methylprednisolone Sodium Hemisuccinate,Methylprednisolone Sodium Succinate,Solu-Medrol,Solumedrol,Urbason-Soluble,Hemisuccinate, Methylprednisolone,Sodium Hemisuccinate, Methylprednisolone,Sodium Succinate, Methylprednisolone,Succinate, Methylprednisolone,UrbasonSoluble
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D011796 Quinacrine An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. Mepacrine,Acrichine,Atabrine,Atebrin,Quinacrine Dihydrochloride,Quinacrine Dihydrochloride, Dihydrate,Quinacrine Dihyrochloride, (R)-Isomer,Quinacrine Dihyrochloride, (S)-Isomer,Quinacrine Dimesylate,Quinacrine Hydrochloride,Quinacrine Monoacetate,Quinacrine Monohydrochloride,Quinacrine Monomesylate,Quinacrine, (+-)-Isomer,Quinacrine, (R)-Isomer,Quinacrine, (S)-Isomer,Dihydrochloride, Quinacrine,Dimesylate, Quinacrine,Hydrochloride, Quinacrine,Monoacetate, Quinacrine,Monohydrochloride, Quinacrine,Monomesylate, Quinacrine
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D002449 Cell Aggregation The phenomenon by which dissociated cells intermixed in vitro tend to group themselves with cells of their own type. Aggregation, Cell,Aggregations, Cell,Cell Aggregations
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D000380 Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS). Granulocytopenia,Agranulocytoses,Granulocytopenias

Related Publications

A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Platelet-activating factor (PAF), a mediator of platelet aggregation. Effect of corticosteroids on PAF-induced platelet aggregation.
January 1980, Minerva nefrologica,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Antibodies to platelet-activating factor (PAF) inhibit PAF-induced platelet aggregation.
November 1991, Journal of lipid mediators,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Role of platelet-activating factor (PAF) in superoxide production by human polymorphonuclear leukocytes.
December 1991, Lipids,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Species differences in platelet aggregation induced by platelet-activating factor (PAF).
November 1992, Methods and findings in experimental and clinical pharmacology,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Aggregation of human polymorphonuclear leukocytes by endothelin: role of platelet-activating factor.
December 1992, European journal of pharmacology,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Platelet-activating factor (PAF)-induced platelet aggregation. Modulation by plasma adenosine and methylxanthines.
November 1994, Biochemical pharmacology,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
[Effect of BN52021 on platelet activating factor induced aggregation of psoriatic polymorphonuclear neutrophils].
June 1994, Zhonghua yi xue za zhi,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Aggregation of equine platelets by PAF (platelet-activating factor).
June 1983, Inflammation,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
[Effect of ginkgolide B on platelet-activating factor induced activation of rat polymorphonuclear leukocytes].
February 2003, Yao xue xue bao = Acta pharmaceutica Sinica,
A Romero, and M A Muniain, and R Mata, and F Pozuelo, and J J Pérez, and M C Rodríguez, and M D Rodríguez
Aspects of PAF (platelet activating factor)-induced aggregation by using rabbit platelets.
December 1982, The Tokushima journal of experimental medicine,
Copied contents to your clipboard!